Balance Labs, Inc.
BLNC · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.40 | 0.45 | 0.00 | 0.04 |
| FCF Yield | -3.42% | -1.41% | 0.15% | -0.43% |
| EV / EBITDA | -26.28 | -94.81 | -13.63 | -31.60 |
| Quality | ||||
| ROIC | 10.69% | 5.61% | 1.34% | -23.65% |
| Gross Margin | 0.00% | 0.00% | 79.86% | 76.71% |
| Cash Conversion Ratio | 0.30 | 0.32 | -0.01 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -37.21% | 472.25% |
| Free Cash Flow Growth | -28.25% | -1,680.06% | 111.68% | 69.54% |
| Safety | ||||
| Net Debt / EBITDA | -9.31 | -20.27 | -4.14 | -3.93 |
| Interest Coverage | -1.17 | -0.52 | -0.10 | 0.92 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,788.97 | -8,388.18 | -8,868.89 | -2,418.45 |